Shareholding for the Period Ended December 31, 2016
Hikal Ltd has submitted to BSE the Shareholding Pattern for the Period Ended December 31, 2016. For more details, kindly Click here17-01-2017
17-01-2017
Newspaper cutting of postal ballot results
Hikal Ltd has submitted to BSE a copy of Newspaper cutting of postal ballot results published on January 13, 2017.13-01-2017
Disclosure of Voting results of Postal Ballot (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Hikal Ltd has informed BSE regarding the details of Voting results of Postal Ballot of the Company held on January 12, 2017, under Regulation 44(3) of SEBI (LODR) Regulations, 2015 along with Scrutinizer's Report.12-01-2017
Hikal (243)
The stock of Hikal jumped 11.5 per cent with strong volumes, decisively breaking through the key 225-230 resistance band on Tuesday. Since taking support at around 120 in early April 2016, the...10-01-2017
Update on the US FDA Inspection at Hikals Bangalore API Facility
Hikal Ltd has informed BSE that the Companys API and Intermediates manufacturing facility located at Jigani, Bangalore was recently inspected by the US FDA in compliance with their requirements. At the end of the successful inspection, the Company have been informed by the Investigator that zero 483 observations were issued. This was a routine inspection by the US FDA.10-01-2017
Hikal sells R&D; property in Bengaluru
The land was lying vacant after Hikal consolidated its R&D operations in Pune in 201405-01-2017
Sale of R&D; Property owned by the Company in Bengaluru
Hikal Ltd has informed BSE regarding "Sale of R&D; Property owned by the Company in Bengaluru".03-01-2017
Notice of Postal Ballot
Hikal Ltd has submitted to BSE a Copy of the Notice of Postal Ballot.09-12-2016
Credit Rating
Hikal Ltd has informed BSE that ICRA Limited [ICRA] (Credit Rating Agency) has upgraded the Companys Long Term Rating from BBB to BBB+. The outlook on Long Term Rating is stable. ICRA has reaffirmed the Short Term Rating of A2.11-11-2016
Hikal (231.8)
Investors with a short-term perspective can consider buying the stock of Hikal, a small-cap pharma company at current levels. On Wednesday, the stock surged 3.6 per cent decisively breaching...10-11-2016